US · Healthcare · Healthcare Plans
EPS came in at 0.50 against a street estimate of 0.44 — a beat of 13.6%.
Analysts rate Progyny Inc a buy (4 buy, 6 hold, 0 sell out of 10) with an average price target of $34.00.
| Fund | Stake |
|---|---|
| BlackRock Inc | 15.32% |
| FMR Inc | 8.30% |
| Vanguard Portfolio Management, LLC | 6.76% |
| Vanguard Capital Management, LLC | 4.44% |
| State Street Corp | 3.93% |
| Ameriprise Financial Inc | 3.61% |
| Fort Washington Investment Advisors Inc | 3.25% |
| Morgan Stanley - Brokerage Accounts | 2.92% |
| Document | Date |
|---|---|
| Charter / bylaws change · Q2 2026 | 2026-05-27 |
| Company announcement · Q2 2026 | 2026-05-26 |
| Quarterly report · Q1 2026 | 2026-05-08 |
| Results announced · Q2 2026 | 2026-05-07 |
| Proxy statement · Q2 2026 | 2026-04-10 |
| Company announcement · Q1 2026 | 2026-03-13 |
| Annual report FY2025 | 2026-02-27 |
| Quarterly report · Q3 2025 | 2025-11-07 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Progyny Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.